MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.

This study is testing whether continuing a PARP inhibitor drug (olaparib) after secondary surgery is better than switching to platinum-based chemotherapy for women with recurrent ovarian, fallopian tube, or peritoneal cancer that has come back after prior PARP inhibitor maintenance therapy. **You may be eligible if...** - You are a woman aged 18 or older - You have high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer that has recurred after first-line PARP inhibitor maintenance - You have received only one prior line of platinum-based chemotherapy (without bevacizumab) - You had complete or partial tumor removal during secondary cytoreductive surgery - Your BRCA gene status has been tested (or you agree to be tested) - You are in good physical condition (ECOG 0 or 1) - Your life expectancy is at least 16 weeks **You may NOT be eligible if...** - You have received more than one prior line of platinum chemotherapy - You could not have your tumor fully removed at secondary surgery - Your prior olaparib use caused significant toxicity requiring permanent dose reduction - You have serious organ problems that would make treatment unsafe Talk to your doctor to see if this trial is right for you.